Nasdaq

Study met both primary and secondary endpoints

STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...
Nasdaq

VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus

ST GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: https://www ...
Business Insider

Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine

- Treatment with KORSUVA Injection resulted in statistically significant reduction in pruritus intensity and improvement in itch-related quality of life measures vs placebo for both primary and ...
Business Wire

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

ST.GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the ...